RSCM
WST icon

Rock Springs Capital Management’s West Pharmaceutical WST Stock Holding History

Rock Springs Capital Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,750
Closed -$2.56M – 111
2025
Q3 		$2.56M Sell
9,750
-41,280
-81% -$10M 0.15% 76
2025
Q2 		$11.2M Sell
51,030
-9,220
-15% -$1.97M 0.7% 50
2025
Q1 		$13.5M Sell
60,250
-108,500
-64% -$29.9M 0.77% 46
2024
Q4 		$55.3M Buy
168,750
+1,000
+0.6% +$315K 2.1% 14
2024
Q3 		$50.4M Buy
167,750
+22,250
+15% +$6.81M 1.64% 20
2024
Q2 		$47.9M Buy
145,500
+8,250
+6% +$2.92M 1.44% 26
2024
Q1 		$54.3M Hold
137,250
– – 1.38% 25
2023
Q4 		$48.3M Sell
137,250
-64,750
-32% -$22.9M 1.19% 28
2023
Q3 		$75.8M Hold
202,000
– – 2.03% 14
2023
Q2 		$77.3M Hold
202,000
– – 1.84% 16
2023
Q1 		$70M Buy
202,000
+16,500
+9% +$4.82M 1.67% 19
2022
Q4 		$43.7M Buy
185,500
+5,000
+3% +$1.18M 1.05% 36
2022
Q3 		$44.4M Buy
180,500
+69,500
+63% +$21.2M 1.15% 28
2022
Q2 		$33.6M Buy
111,000
+41,750
+60% +$13.6M 0.98% 35
2022
Q1 		$28.4M Buy
69,250
+23,750
+52% +$9.3M 0.72% 46
2021
Q4 		$21.3M Buy
45,500
+15,500
+52% +$6.67M 0.49% 63
2021
Q3 		$12.7M Buy
30,000
+1,500
+5% +$632K 0.27% 95
2021
Q2 		$10.2M Hold
28,500
– – 0.2% 112
2021
Q1 		$8.03M Hold
28,500
– – 0.18% 123
2020
Q4 		$8.07M Hold
28,500
– – 0.17% 121
2020
Q3 		$7.83M Sell
28,500
-42,500
-60% -$11.2M 0.2% 112
2020
Q2 		$16.1M Hold
71,000
– – 0.44% 76
2020
Q1 		$10.8M Sell
71,000
-81,500
-53% -$12.5M 0.45% 72
2019
Q4 		$22.9M Hold
152,500
– – 0.72% 53
2019
Q3 		$21.6M Buy
152,500
+15,000
+11% +$2.07M 0.86% 42
2019
Q2 		$17.2M Buy
137,500
+12,500
+10% +$1.48M 0.62% 58
2019
Q1 		$13.8M Sell
125,000
-35,000
-22% -$3.64M 0.53% 63
2018
Q4 		$15.7M Hold
160,000
– – 0.74% 40
2018
Q3 		$19.8M Hold
160,000
– – 0.72% 48
2018
Q2 		$15.9M Buy
+160,000
New +$14.7M 0.61% 60

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Rock Springs Capital Management's WST Position: Q4 2025 in Review

Rock Springs Capital Management sold out of West Pharmaceutical (WST) in Q4 2025, closing a stake of 9,750 shares — an estimated $2.56M sold.

Rock Springs Capital Management first reported a position in WST in Q2 2018 and held it in 30 quarters. The position peaked at $77.3M in Q2 2023. 804 funds tracked by Wall St. Rank hold WST as of Q4 2025.

  • Rock Springs Capital Management reported no remaining West Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Rock Springs Capital Management sold 9,750 West Pharmaceutical shares in Q4 2025, an estimated $2.56M.
  • Rock Springs Capital Management first reported a position in West Pharmaceutical in Q2 2018 and held it in 30 quarters.
  • Rock Springs Capital Management's West Pharmaceutical position peaked at $77.3M in Q2 2023.
  • 804 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2025.

Based on Rock Springs Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.